Close Menu

NEW YORK – Diagnostics makers have begun bringing serology tests for SARS-CoV-2 to market, raising the prospect that these assays could help scientists and policy makers better assess the scope of the pandemic and perhaps identify individuals with antibodies against the virus who could safely return to work.

The likely low prevalence of COVID-19 in the general population presents a challenge to such testing, however, as tests without extremely high accuracy could lead to large numbers of incorrect results, resulting in dangerous consequences.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 


As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.